Business Wire

Panasonic Starts Licensing IP Core for Semiconductors Complying with the IEEE 1901–2020 International Standard

16.3.2021 03:13:00 CET | Business Wire | Press Release

Share

Panasonic Corporation has begun licensing the HD-PLCTM 4*1 IP core required for the design of semiconductors with technologies and functions that comply with the IEEE 1901–2020*2 international standard. This IP core is the fourth generation of the HD-PLC series. Although conventionally HD-PLC have used power lines for transmission, this new series enables transmission through existing metal wires, such as control lines and coaxial cables as well as power lines, expanding its range of applications. This new HD-PLC technology also enables higher speeds, greater distance, and less wiring for wired communications.

By using this IP core, semiconductor and peripheral equipment manufacturers will be able to flexibly meet to a range of IoT service requirements and manufacture products that respond to these needs.

As a wide range of equipment in society becomes digitalized and connects to the IoT devices, communication technologies are becoming increasingly important. While the adoption of wireless technologies such as 5G and high-speed fiber optic internet gains pace, there are some locations in which it is difficult to access wireless communication. Here, the use of existing metal wires—in the walls and ceilings of buildings, underground facilities, and equipment—as communication mediums fulfils a vital role. This IP core is a solution that can rapidly meet to the requirements of the era of IoT, such as higher-speed networks, enhanced security, and internet protocol networks. By combining the IP core with wireless and other technologies, it can help create optimal networks in a range of environments, from living spaces to social infrastructure.

Using its experience and achievements with the HD-PLC 3 IP core, which is currently on the market, in addition to licensing of this new IP core, Panasonic will provide one-stop development support to users which will include proposals for analog front-end circuitry—key to the mounting of semiconductors. Further, as a high-speed wired communication solution, Panasonic will seek to use this technology to expand the adoption of IoT PLC, ultimately applying the technology to large-scale networks that cover living spaces, buildings, factories, smart cities, and other social infrastructure.

This IP core is first licensed to Socionext Inc. This enables the supply of higher performance semiconductors with lower energy consumption using fourth generation HD-PLC. It is expected that these will then be built-in to a range of IoT-connected devices.

Panasonic launched a dedicated website with more information about this technology. Please note that the global IEEE SA and HD-PLC Alliance*3 Webinar will be held on March 18, 2021.

Main Features

  • The standard mode communication band (250 Mbps) can be doubled or quadrupled, allowing a 500 Mbps*4 communication speed in double mode or a maximum of 1 Gbps*4 in quadruple mode on coaxial cable or dedicated line.
  • The standard mode communication band can be compressed on two levels (half or quarter), concentrating and extending the communication distance up to twice*5 the distance in standard mode.
  • With the multi-hop function, it is possible to operate a wide area network of up to 1024 nodes.

Main Specifications

Communication
bandwidth

High-speed mode (1 Gbps, 500 Mbps) *Optional

Standard mode (250 Mbps)

Long-distance mode (2 x or 1.5 x the range of standard mode)

Approved
standards

IEEE 1901-2020

ITU-T G.9972 (Coexistence mechanism for different PLC systems)

ITU-T G.9905 (Multi-hop) *Optional

EN 50561-1:2013 (Dynamic notch and dynamic power control)

Inquiries Regarding IP Core Licensing
IoT PLC Project Help Desk
Email: hd-plc_press@ml.jp.panasonic.com
Website: https://www.panasonic.com/global/business/hd-plc/en.html

*1: HD-PLCTM is the name of the high-speed power line communications system proposed by Panasonic Corporation, and is a trademark or registered trademark of Panasonic Corporation in Japan and other countries. HD-PLCTM 4 is the name of the fourth-generation semiconductor IP core.
*2: Formulated by the IEEE Standards Association (a communication standards subsidiary of the Institute of Electrical and Electronics Engineers) on January 19, 2021, this is a standard for technologies with higher speeds and longer distances than those outlined in IEEE 1901-2010.
IEEE 1901-2020 - IEEE Standard for Broadband over Power Line Networks: Medium Access Control and Physical Layer Specifications: https://standards.ieee.org/standard/1901-2020.html
*3: An alliance formed on September 25, 2007, to support, promote and implement the HD-PLC system for High-Speed Power Line Communications and to ensure mutual compatibility.
Website: https://hd-plc.org/
*4: 500 Mbps and 1 Gbps are theoretical speeds at the physical layer.
*5: Maximum distance may change depending on communication environment.

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 528 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

Source: https://news.panasonic.com/global/press/data/2021/03/en210316-2/en210316-2.html

Related Links
IEEE SA and HD-PLC Alliance Webinar March 2021: Home Networking, Industrial and Building Automation through HD-PLC (High Speed Powerline Communication)
https://standards.ieee.org/events/index.html

[Press Release] Panasonic's Next-generation HD-PLC®, BPL Communication Technology Adopted as IEEE 1901a Standard
https://news.panasonic.com/global/press/data/2019/03/en190325-4/en190325-4.html

Socionext Inc. related press release
https://www.socionext.com/en/pr/sn_pr20210309_01e.pdf

HD-PLC Alliance
https://hd-plc.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Inquiries Regarding IP Core Licensing
IoT PLC Project Help Desk
Email: hd-plc_press@ml.jp.panasonic.com
Website: https://www.panasonic.com/global/business/hd-plc/en.html

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye